Hearing News Watch

by Terry Mactaggart, President and CEO, Summus Hearing The last three posts have focused on supply – how current, new, and potentially other providers could “Move the Meter”, making inroads on confronting the Hearing Health Problem. The corollary question involves the demand side of the equation, making hearing health maintenance more understood, relevant, and approachable to and for the Public.

The American Academy of Audiology has announced the recipients of its 2026 Academy Honors and Awards, recognizing individuals who have made significant and lasting contributions to audiology and the hearing sciences. Each year, the Academy invites colleagues, mentors, and peers to nominate professionals whose work reflects excellence in clinical care, research, education, advocacy, and service to the profession. According to

HANOVER, GERMANY — The European Union of Hearing Aid Acousticians (EUHA) has opened submissions for the EUHA Sponsorship Award 2026, inviting entries from the fields of audiology, hearing aid fitting, and customer benefit research through 15 August 2026. Now in its 15th year, the award has become a well-established part of the hearing care industry’s professional calendar. The EUHA Sponsorship

MILAN, ITALY — More than 1,000 Amplifon employees across 26 countries participated in an internal initiative titled “75 Years of Emotions,” created to mark the 75th anniversary of the company’s founding. Amplifon, an Italian multinational hearing care company, was established in Milan in 1950 by Charles Holland. The initiative ran for approximately three months and invited employees to submit photographs

Tinnitus clinical services are not consistently standardized, and there is currently no widely adopted system for credentialing clinician competency in tinnitus care. Although multiple research-based methods exist for the clinical management of tinnitus, no single approach has been proven more effective than the others, and differences in methodology can result in different outcomes. Authored by James A. Henry, PhD, Tinnitus

MILAN, ITALY – Amplifon, the global leader in hearing services and solutions, has launched its new global holiday campaign, The Wish, celebrating the role of listening as one of the most meaningful gifts we can offer our loved ones. The campaign features photographic stories of a grandmother and her grandson, a father and daughter, and a couple sharing a moment

MONTPELLIER, FRANCE — Sensorion announced that the independent Data Monitoring Committee (DMC) has identified no safety concerns and supports continued enrollment in the Audiogene Phase 1/2 clinical trial evaluating SENS-501, the company’s investigational gene therapy designed to treat a rare form of congenital deafness caused by mutations in the OTOF (otoferlin) gene. The committee’s review included favorable procedural tolerance and no

TAMPA, FLORIDA — HearUSA announced the launch of its Wonderful Sound for All initiative in partnership with the Hearing Aid Project (HAP), a program of Sertoma International, aimed at expanding access to hearing care for individuals facing financial barriers. Through the initiative, qualified individuals will be able to receive free hearing aids, hearing screenings, and audiology services at HearUSA hearing

RESEARCH TRIANGLE PARK, N.C. — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection) for reducing cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan. PEDMARK® is the first and only U.S. Food

SEATTLE, WASHINGTON — Sound Pharmaceuticals (SPI) announced that the U.S. Food and Drug Administration (FDA) has granted its investigational drug, SPI-1005, Breakthrough Therapy Designation (BTD) for the treatment of hearing loss associated with Meniere’s disease (MD). MD is a complex inner ear disorder involving low-to-mid frequency hearing loss, tinnitus, vertigo, and dizziness. This marks the first BTD granted for a